


Data Sheet

Product Name:	AH 6809
Cat. No.:	CS-1549
CAS No.:	33458-93-4
Molecular Formula:	C ₁₇ H ₁₄ O ₅
Molecular Weight:	298.29
Target:	Prostaglandin Receptor
Pathway:	GPCR/G Protein
Solubility:	H ₂ O : < 0.1 mg/mL (insoluble); DMSO : 25 mg/mL (83.81 mM); Need ultrasonic)



BIOLOGICAL ACTIVITY:

AH 6809 is an EP and DP receptor antagonist with nearly equal affinity for the cloned human EP₁, EP₂, EP₃-III, and DP₁ receptors. IC₅₀ Value: ~3 nM (EC₅₀ for calcium mobilization by PGE₂) [1] Target: EP/DP receptor in vitro: AH6809 also antagonized the aggregatory effect of U-46619 in whole blood (pA₂ = 4.45). However, concentrations of AH6809 up to 300 microM were without effect upon either ADP- or platelet activating factor (Paf)-induced aggregation (pA₂ less than 3.5) [2]. Preincubation of control cells in 10⁻⁴ M concentrations of AH6809 inhibited PGE₂-induced activation of AC by greater than 80% without significant (P greater than .05) inhibition of basal activity by the antagonist [3]. in vivo: Exposure to a selective COX-2 inhibitor (SC58125) or an EP₁/EP₂ antagonist (AH6809), but not an EP₄ antagonist (AH23848B), significantly reduced cell proliferation of esophageal explants in 24 hour-organ culture experiments [4]. Oral administration of the EP₁ receptor antagonist, AH6809 (10 mg/kg/day, for 4 days), significantly reduced the systolic blood pressure in db/db, but not in control mice [5].

References:

- [1]. [http://www.millipore.com/publications.nsf/a73664f9f981af8c852569b9005b4eee/cae2c825891fb78e85257b19005fa865/\\$FILE/HTS099C%20ep1%20datasheet%2012](http://www.millipore.com/publications.nsf/a73664f9f981af8c852569b9005b4eee/cae2c825891fb78e85257b19005fa865/$FILE/HTS099C%20ep1%20datasheet%2012)
- [2]. Keery RJ, et al. AH6809, a prostaglandin DP-receptor blocking drug on human platelets. Br J Pharmacol. 1988 Jul;94(3):745-54.
- [3]. Capehart AA, et al. Effects of a putative prostaglandin E₂ antagonist, AH6809, on chondrogenesis in serum-free cultures of chick limb mesenchyme. J Cell Physiol. 1991 Jun;147(3):403-11.
- [4]. Piazzuelo E, et al. Characterization of the prostaglandin E₂ pathway in a rat model of esophageal adenocarcinoma. Curr Cancer Drug Targets. 2012 Feb;12(2):132-43.
- [5]. Rutkai I, et al. Activation of prostaglandin E₂ EP₁ receptor increases arteriolar tone and blood pressure in mice with type 2 diabetes. Cardiovasc Res. 2009 Jul 1;83(1):148-54.

CAIndexNames:

9H-Xanthene-2-carboxylic acid, 6-(1-methylethoxy)-9-oxo-

SMILES:

O=C1C2=C(C=CC(C(O)=O)=C2)OC3=CC(OC(C)C)=CC=C31

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA